for scleral perforation, particularly for trainee surgeons. Ambidexterity can be achieved with practice over a period of time under an operating microscope.
Sir, Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy The treatment of juxtapapillary retinal capillary haemangioma (RCH) raises difficulties because of the vicinity to the optic nerve. As juxtapapillary RCHs are frequently located at the temporal site of the disk, 1, 2 chronic leakage often threatens the macula. 3 Photodynamic therapy (PDT) with verteporfin has shown to succeed in shrinking RCH, but repeated treatment often resulted in poor functional results. 2, 3 We report on a case of juxtapapillary RCH, successfully treated with a combination of intravitreal bevacizumab and PDT. 6 mg/m 2 over 10 min) was performed with an irradiation time of 166 s. Four weeks after the PDT, the tumour showed marked regression and an increase in VA to 20/25. Perimetry also revealed regression of the scotoma to a small inferotemporal spot. One year after the therapy, the macula remained dry and VA was 20/25 ( Figure 2 ).
Comment
The case presented underlines that bevacizumab treatment alone can cause a reduction of the tumour-associated exudation, presumably by depleting endothelial fenestrae and altering intercellular adhesion molecules. 4 Vascular complications and phototoxicity are most likely the reasons for the vision loss after PDT in juxtapapillary RCH. 2 The anti-exudative effect of bevacizumab promises better delineation of the juxtapapillary RCH and consequently allows more precisely adjustment of the PDT irradiation to minimize the collateral damage. The single combination therapy of bevacizumab and PDT had a longlasting effect and thus eliminated the necessity of further destruction by repeated PDT. 5 Long-term follow-up of other cases is necessary to make a conclusive statement about the combination therapy of juxtapapillary RCH. 
